Cargando…

PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status

Prostate cancer (PCa) is the most common malignancy in men worldwide, leading to substantial morbidity and mortality. At present, imaging of PCa has become increasingly important for staging, restaging, and treatment selection. Until recently, choline-based positron emission tomography/computed tomo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lütje, Susanne, Heskamp, Sandra, Cornelissen, Alexander S., Poeppel, Thorsten D., van den Broek, Sebastiaan A. M. W., Rosenbaum-Krumme, Sandra, Bockisch, Andreas, Gotthardt, Martin, Rijpkema, Mark, Boerman, Otto C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4672020/ https://www.ncbi.nlm.nih.gov/pubmed/26681984 http://dx.doi.org/10.7150/thno.13348

Ejemplares similares

PSMA-targeting agents for radio- and fluorescence-guided prostate cancer surgery
por: Derks, Yvonne H.W., et al.
Publicado: (2019)

Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors
por: Lütje, Susanne, et al.
Publicado: (2019)

Photosensitizer-based multimodal PSMA-targeting ligands for intraoperative detection of prostate cancer
por: Derks, Yvonne H.W., et al.
Publicado: (2021)

Optimization of Acquisition time of (68)Ga-PSMA-Ligand PET/MRI in Patients with Local and Metastatic Prostate Cancer
por: Lütje, Susanne, et al.
Publicado: (2016)

Imaging and photodynamic therapy of prostate cancer using a theranostic PSMA-targeting ligand
por: Derks, Yvonne H. W., et al.
Publicado: (2023)

Strain-Promoted Azide–Alkyne Cycloaddition-Based PSMA-Targeting Ligands for Multimodal Intraoperative Tumor Detection of Prostate Cancer
por: Derks, Yvonne H. W., et al.
Publicado: (2021)

Theranostic PSMA ligands with optimized backbones for intraoperative multimodal imaging and photodynamic therapy of prostate cancer
por: Derks, Yvonne H. W., et al.
Publicado: (2022)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer
por: Wierstra, Peter, et al.
Publicado: (2019)

Enhanced Specific Activity by Multichelation of Exendin-3 Leads To Improved Image Quality and In Vivo Beta Cell Imaging
por: Joosten, Lieke, et al.
Publicado: (2017)

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer
por: Müller, Cristina, et al.
Publicado: (2019)

Towards Personalized Treatment of Prostate Cancer: PSMA I&T, a Promising Prostate-Specific Membrane Antigen-Targeted Theranostic Agent
por: Chatalic, Kristell L.S., et al.
Publicado: (2016)

(213)Bi-PSMA-617 targeted alpha-radionuclide therapy in metastatic castration-resistant prostate cancer
por: Sathekge, Mike, et al.
Publicado: (2017)

Advances in (177)Lu-PSMA and (225)Ac-PSMA Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
por: Ling, Sui Wai, et al.
Publicado: (2022)

A perspective on the EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands
por: Gericke, Germo
Publicado: (2021)

A pretargeted multimodal approach for image-guided resection in a xenograft model of colorectal cancer
por: Elekonawo, Fortuné M. K., et al.
Publicado: (2019)

Precision strikes: PSMA-targeted radionuclide therapy in prostate cancer – a narrative review
por: Szponar, Paweł, et al.
Publicado: (2023)

EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides
por: Handkiewicz-Junak, Daria, et al.
Publicado: (2018)

PSMA ligands for diagnosis and therapy of prostate cancer
por: Haberkorn, Uwe
Publicado: (2014)

Preclinical Assessment of the Combination of PSMA-Targeting Radionuclide Therapy with PARP Inhibitors for Prostate Cancer Treatment
por: Ruigrok, Eline A. M., et al.
Publicado: (2022)

Preventing Radiobleaching of Cyanine Fluorophores Enhances Stability of Nuclear/NIRF Multimodality Imaging Agents
por: Hernandez, Reinier, et al.
Publicado: (2017)

Extensive preclinical evaluation of lutetium-177-labeled PSMA-specific tracers for prostate cancer radionuclide therapy
por: Ruigrok, Eline A. M., et al.
Publicado: (2020)

Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
por: Arbuznikova, Daria, et al.
Publicado: (2023)

Combining Targeted Radionuclide Therapy and Immune Checkpoint Inhibition for Cancer Treatment
por: Kleinendorst, Simone C., et al.
Publicado: (2022)

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model
por: Merkx, Robin I. J., et al.
Publicado: (2022)

Clinical Variables Associated with PSA Response to Lutetium-177-PSMA ([177Lu]-PSMA-617) Radionuclide Treatment in Men with Metastatic Castration-Resistant Prostate Cancer
por: Gadot, Moran, et al.
Publicado: (2020)

The Future of PSMA-Targeted Radionuclide Therapy: An Overview of Recent Preclinical Research
por: Ruigrok, Eline A.M., et al.
Publicado: (2019)

(18)F-Labelled exendin to image GLP-1 receptor-expressing tissues: from niche to blockbuster?
por: Boerman, Otto C., et al.
Publicado: (2011)

Decision-support for treatment with (177)Lu-PSMA: machine learning predicts response with high accuracy based on PSMA-PET/CT and clinical parameters
por: Moazemi, Sobhan, et al.
Publicado: (2021)

Estimating the Potential of Radiomics Features and Radiomics Signature from Pretherapeutic PSMA-PET-CT Scans and Clinical Data for Prediction of Overall Survival When Treated with (177)Lu-PSMA
por: Moazemi, Sobhan, et al.
Publicado: (2021)

Heterogeneity of prostate-specific membrane antigen (PSMA) and PSMA-ligand uptake detection combining autoradiography and postoperative pathology in primary prostate cancer
por: Wang, Hui, et al.
Publicado: (2023)

2021: the year [(177)Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines?: Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke
por: Herrmann, Ken, et al.
Publicado: (2021)

PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports
por: Uijen, M. J. M., et al.
Publicado: (2021)

Lutetium (177) PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy
por: Emmett, Louise, et al.
Publicado: (2017)

Imaging carbonic anhydrase IX as a method for monitoring hypoxia-related radioresistance in preclinical head and neck cancer models
por: Huizing, Fokko J., et al.
Publicado: (2021)

Machine Learning Facilitates Hotspot Classification in PSMA-PET/CT with Nuclear Medicine Specialist Accuracy
por: Moazemi, Sobhan, et al.
Publicado: (2020)

Quantitative Imaging of the Hypoxia-Related Marker CAIX in Head and Neck Squamous Cell Carcinoma Xenograft Models
por: Huizing, Fokko J., et al.
Publicado: (2018)

(68)Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study
por: van Boxtel, Wim, et al.
Publicado: (2020)

Evaluating a Machine Learning Tool for the Classification of Pathological Uptake in Whole-Body PSMA-PET-CT Scans
por: Erle, Annette, et al.
Publicado: (2021)

Single-lesion Prostate-specific Membrane Antigen Protein Expression (PSMA) and Response to [(177)Lu]-PSMA-ligand Therapy in Patients with Castration-resistant Prostate Cancer
por: Stangl-Kremser, Judith, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dt1oul1cdlhgg0q7rat1l6npfi